Pursuant to the Second Interim Award:
- Back royalties related to fiscal year 2022 of approximately
- A separate Know-How Royalty (as defined in the applicable license agreement) term applies for each of INVEGA SUSTENNA®, INVEGA TRINZA® and INVEGA HAFYERA®, as follows:
- The term for INVEGA SUSTENNA ends on
Aug. 20, 2024 . - The term for INVEGA TRINZA ends in the second quarter of 2030 (but no later than
May 2030 when the applicable license agreement expires). - The term for INVEGA HAFYERA ends in
May 2030 (when the applicable license agreement expires).
- Royalties for CABENUVA® in the
The Tribunal directed the parties to confer and advise within 21 days concerning the rate of interest and proposed further proceedings, including whether any issues remain for resolution by the Tribunal prior to the Tribunal's issuance of a final award.
The Second Interim Award follows the Interim Award issued by the Tribunal on
In accordance with the license agreements, the arbitration is being conducted pursuant to the
About
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the company's expectations regarding the back royalties and interest due to the company under the license agreements with Janssen, the respective duration of the royalty term for each product under the license agreements and expectations regarding further proceedings before the Tribunal, if any. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others, that the terms of the final award to be issued by the Tribunal may differ from the terms of the interim awards issued by the Tribunal and may be challenged, and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2022 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("
INVEGA SUSTENNA®, INVEGA TRINZA®, and INVEGA HAFYERA® are registered trademarks of Johnson & Johnson or its affiliated companies. CABENUVA® is a registered trademark of ViiV Healthcare
Alkermes Contacts:
For Investors:
For Media: Katie Joyce, +1 781 249 8927
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-second-interim-award-in-janssen-pharmaceutica-arbitration-301806110.html
SOURCE